Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology

Author(s): G. N. Chaldakov, I. S. Stankulov, M. Hristova, P. I. Ghenev.

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 12 , 2003

Become EABM
Become Reviewer

Abstract:

In recent years, the simple paradigm of adipose tissue as merely a fat store is rapidly evolving into a complex paradigm of this tissue as multipotential secretory organ, partitioned into a few large depots, including visceral and subcutaneous location, and many small depots, associated with a variety of organs in the human body. The major secretory compartment of adipose tissue consists of adipocytes, fibroblasts, and mast cells. These cells, using endocrine, paracrine and autocrine pathways, secrete multiple bioactive molecules, conceptualized as adipokines or adipocytokines. This review examines current information in adipobiology of various diseases besides obesity and related diseases such as type 2 diabetes, metabolic syndrome, and cardiovascular disease. Finally, we emphasize the possibilities for adipokine-targeted pharmacology in adiponectin (Acrp30, apM1, AdipoQ, GBP28), angiotensin II, estrogens, nerve growth factor, tumor necrosis factor-a, and also adipose mast cells.

Keywords: adipobiology, adipokines, adipokine targeted pharmacology, adipose tissue, adiponectin, angiotensin II, adipose mast cells

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 12
Year: 2003
Page: [1023 - 1031]
Pages: 9
DOI: 10.2174/1381612033455152
Price: $58

Article Metrics

PDF: 7